The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the U.S., underscoring the challenges the Swiss drugmaker will face in promoting the potential blockbuster.
The cost of the leukemia treatment, called Kymriah, is “dramatically higher” than other such complex treatments, and the health-care system isn’t ready to pay for it, Steve Miller, chief medical officer at Express Scripts Holding Co., said Thursday in a blog post on his company’s website. Gene therapies like Novartis’s are targeted at a small number of patients and typically used just once, meaning that drug companies have limited chances to recoup their investment.
Related: Pharmacy benefits ripe for reform?
“Therein lies the challenge,” Miller wrote. “We need a new payment model.”
Kymriah is the first drug approved from a new class of treatments called CAR-Ts that have been heralded as a promising approach to treating and potentially curing cancers as well as genetic conditions such as blindness. Paying for CAR-Ts and similar therapies, some of which cost as much as $1.4 million, will require new collaborative approaches among payers, drugmakers and policymakers, the executive wrote.
|Cost Hurdle
Novartis has said it will attempt to address the pricing hurdle with a new type of agreement: for patients whose care is covered by U.S. government programs, the company will get paid only if patients show signs that the treatment is working within a month of getting it.
Other value-based payment approaches for Kymriah and CAR-T therapies are under discussion, Novartis said Friday in an emailed statement. Studies show its drug would still be cost-effective at $600,000 to $750,000 for treating leukemia, while the only other potentially curative option for young patients is a stem-cell transplant costing $500,000 to $800,000 for the first year.
“We are committed to doing everything we can to help children and young adults who can benefit from Kymriah have access to the therapy,” the company said. “We are working with payers to ensure they fully understand the value of Kymriah and provide coverage for patients.”
Shares of the Swiss company rose 0.5 percent to 83.35 Swiss francs as of 12:18 p.m. in Zurich.
Express Scripts, a pharmacy benefit manager in the U.S., negotiates prices with drugmakers to lower costs for its clients, which include employers and insurers.
The approval of Novartis’s CAR-T therapy last month came just two days after Gilead Sciences Inc. announced an $11.9 billion deal to buy Kite Pharma Inc., which is developing a rival CAR-T therapy scheduled for an FDA ruling by Nov. 29.
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
